EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials

Yingge Lv, Hua Zhao, Shaochuan Liu, Yuan Meng iD, Wenwen Yu, Ting Liu, Qian Sun, Meng Shen, Xiubao Ren, Liang Liu

Journal of Leukocyte Biology · 2024

DOI: 10.1093/jleuko/qiae037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2024. Verfasst von Yingge Lv und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 30006…. Hauptthemen laut MEDLINE: Quinolines, Indoles, Cytokine-Induced Killer Cells, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Tianjin Key Medical Discipline, Tianjin Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Murine cytokine-induced killer (CIK) cells are heterologous cells that kill various allogeneic and isogenic tumors and have functional and phenotypic characteristics of natural killer cells and T lymphocytes. However, the effect of CIK cells alone on solid tumor therapy is only limited. To enhance the therapeutic effect, it is vital to discover a mix of several therapy approaches. Immune cell function is inhibited by abnormal tumor vessels and the tumor microenvironment, which block lymphocyte entry into tumor tissue. To increase the effectiveness of CIK cells’ antitumor activity, antivascular therapy and CIK cell therapy can be combined. Furthermore, anlotinib is a tiny drug with multitarget tyrosine kinase inhibitors that can block cell migration, delay angiogenesis, and decrease blood vessel density. Compared with other antiangiogenesis drugs, anlotinib stands out due to the wider target of action and lower effective dose. In this work, anlotinib and murine CIK cells were coupled to boost CD3+ T cell infiltration, CD3+CD4+ T cell infiltration, and expression of granzyme B and interferon γ from CD3+CD8+ T cells, which increased the antitumor activity. Through the generation of cytotoxic cytokines by T lymphocytes, the therapeutic group using anti-PD-1 monoclonal antibodies in conjunction with anlotinib and CIK cells was more successful than the group receiving dual therapy. The preclinical study contributes to exploring the therapeutic alternatives for patients with lung adenocarcinoma, thus prolonging their lives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesIndolesCytokine-Induced Killer CellsLung NeoplasmsProgrammed Cell Death 1 ReceptorAnimalsMiceAdenocarcinoma of LungHumansCell Line, TumorImmune Checkpoint InhibitorsAntibodies, MonoclonalMice, Inbred C57BLFemale

Stichwörter der Autor:innen

IFN-γanlotinibanti-PD-1 monoclonal antibodygranzyme Bmurine CIK cellstumor-infiltrating lymphocytes

Substanzen

QuinolinesanlotinibIndolesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntibodies, MonoclonalPdcd1 protein, mouse

Autor:innen und Institutionen

  • Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China.
  • Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China.
  • Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China.
  • Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China.
  • Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China.
  • Haihe Laboratory of Cell Ecosystem, Yuexin Road, Binhai New District, Tianjin, 300060, China.

ORCID-Profile: Yuan Meng

Förderung

  • National Natural Science Foundation of China
  • Tianjin Key Medical Discipline
  • Tianjin Natural Science Foundation
  • Haihe Laboratory of Cell Ecosystem Innovation Fund
  • 22HHXBSS00004

Zitieren

APA

Lv, Y., Zhao, H., Liu, S., Meng, Y., Yu, W., Liu, T., Sun, Q., Shen, M., Ren, X., & Liu, L. (2024). Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae037

Vancouver

Lv Y, Zhao H, Liu S, Meng Y, Yu W, Liu T, et al. Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials. Journal of Leukocyte Biology. 2024. doi:10.1093/jleuko/qiae037

BibTeX
@article{Lv2024,
  author = {Lv, Yingge and Zhao, Hua and Liu, Shaochuan and Meng, Yuan and Yu, Wenwen and Liu, Ting and Sun, Qian and Shen, Meng and Ren, Xiubao and Liu, Liang},
  title = {Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials},
  journal = {Journal of Leukocyte Biology},
  year = {2024},
  doi = {10.1093/jleuko/qiae037}
}
Kostenlos starten →